NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL

Volkmann E, Castellvi I, Johnson S, Matteson E, Distler J, Seibold J, Costabel U, James A, Coeck C, Quaresma M, Cottin V (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 1015-1015

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

Event location: , ELECTR NETWORK

DOI: 10.1136/annrheumdis-2020-eular.2322

Authors with CRIS profile

Jörg Distler Professur für Molekulare Mechanismen der Organfibrose

Involved external institutions

Boehringer Ingelheim Pharma GmbH & Co. KG

Germany (DE) Mayo Clinic

United States (USA) (US) University of Toronto

Canada (CA) Scleroderma Research Consultants LLC

United States (USA) (US) Université Claude Bernard Lyon 1 (UCB)

France (FR) University of California Los Angeles (UCLA)

United States (USA) (US) SCS Boehringer Ingelheim Comm.V.

Belgium (BE) Hospital de la Santa Creu i Sant Pau

Spain (ES) Universität Duisburg-Essen (UDE)

Germany (DE)

How to cite

APA:

Volkmann, E., Castellvi, I., Johnson, S., Matteson, E., Distler, J., Seibold, J.,... Cottin, V. (2020). NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL. In ANNALS OF THE RHEUMATIC DISEASES (pp. 1015-1015). , ELECTR NETWORK: LONDON: BMJ PUBLISHING GROUP.

MLA:

Volkmann, E., et al. "NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL." Proceedings of the Annual European Congress of Rheumatology (EULAR), , ELECTR NETWORK LONDON: BMJ PUBLISHING GROUP, 2020. 1015-1015.

BibTeX: Download